Emmanuelle di Tomaso

Bayer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

52h-index20.0kcitations185works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(35), Angiogenesis and VEGF in Cancer(32), HER2/EGFR in Cancer Research(27), Glioma Diagnosis and Treatment(22), Advanced Breast Cancer Therapies(21)

Publications185 total

1200 Artificial intelligence image models optimizing tumor vs immune cell profiling for accurate biomarker analysis in NSCLC precision drug development
Regular and Young Investigator Award Abstracts·2024Open Access
1276 Leveraging artificial intelligence (AI) models delineating tumor vs immune cell expression for scalable biomarker analysis of clinical trial samples: a digital image analysis approach for NSCLC
Regular and Young Investigator Award Abstracts·2023Open Access
Supplementary Figure 1 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
Supplementary Figure 3 from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
2023Open Access
Data from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
2023Open Access
Supplementary Table 1 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
Supplementary Table 2 from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
2023Open Access
Supplementary Table 4 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
Supplementary Table 6 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
Supplementary Figure 3 from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
2023Open Access
Supplementary Methods from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
2023Open Access
Supplementary Table 5 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
Supplementary Table 1 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
Data from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
Supplementary Table 2 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
Supplementary Tables S1-S7 from Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value
2023Open Access
Supplementary Figure 1 from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
2023Open Access
Supplementary Figure 2 from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
2023Open Access
Data from Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value
2023Open Access
Supplementary Figure 1 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Rakesh K. Jain(30), Dan G. Duda(16), Lance L. Munn(9), Yves Boucher(8), A. Gregory Sorensen(8), Marek Ancukiewicz(8), Christopher G. Willett(7), Tracy T. Batchelor(7), Cristian Massacesi(7), Jeffrey W. Clark(6), Scott R. Plotkin(6), Timothy P. Padera(6), Kenneth S. Cohen(5), Paul C. Shellito(5), Gregory Y. Lauwers(5), Patrick Y. Wen(5), Dai Fukumura(5), Patrick Urban(5), Johanna Lahdenranta(5), Ricky T. Tong(4)